Search bioRxiv⌕ Search

Biology subjects

Roemer, A. M. A.

Publications and source records attributed to Roemer, A. M. A..

2 recordsLinked to original sources

Collagen type I promotes pancreatic tumor growth and limits immune cell infiltration

Solid tumors are often characterized by a dense extracellular matrix (ECM) that contributes to increased tissue stiffness. Collagen type I is the main component of the ECM and its abundance in tumors is frequently associated with poor prognosis. In vitro studies suggest that a high collagen density promotes tumor invasion and modulates immune responses. However, recent in vivo findings have questioned the pro-tumorigenic role of collagen type I. In this study, we investigate the role of collagen for pancreatic tumor growth and immune cell infiltration using conditional collagen type I knockout mice and transgenic collagenase-resistant mice. Preventing collagen type I significantly reduces intratumoral collagen content and tumor growth. This reduction is accompanied increased infiltration of natural killer (NK) cells, a higher CD8/CD4 T cell ratio, and decreased numbers of monocytic myeloid-derived suppressor cells (MDSCs). Conversely, collagenase-resistant mice develop collagen-dense tumors and display enhanced tumor growth. These mice also generally exhibit opposing effects on cell infiltration, including a lower CD8/CD4 ratio and increased MDSC abundance. These findings are further supported by analyses of publicly available human cancer datasets, which confirm an association between collagen type I levels and immune cell infiltration. Overall, our results demonstrate a pronounced pro-tumorigenic role of collagen type I in pancreatic cancer, which is associated with modulation of the tumor immune microenvironment. This study highlights the importance of extracellular matrix components as key regulators of tumor progression and anti-tumor immunity.

cancer biology↗

Contact-based thymidylate transfer promotes collective tumor growth

Sustained cell proliferation is a fundamental hallmark of cancer, yet its mechanism remains elusive, particularly in context of heterogenous tumor organization, intercellular interactions, and metabolite exchanges. In this study, we uncover a mechanism of tumor growth via collective proliferation, where cells connected by gap junctions enable equilibration of thymidylate (dTMP) to allow the proliferation of cells lacking canonical de novo dTMP biosynthesis and salvage driven by thymidylate synthase (TYMS) and thymidine kinase 1 (TK1) enzymes, respectively. Collective proliferation is driven by dTMP-proficient cancer cells alongside cells of varied origins, such as macrophages and endothelial cells. The mechanism is also observed in clinical samples and is validated in a genetic mouse model of lung cancer harboring dual Tyms/Tk1 tumor-specific knockout, in which tumors grow despite lacking enzymatic dTMP synthesis and tumor progression is opposed by gap junction inhibition. Data further hint that this mechanism is critical driver of tumor pathophysiology, influencing key processes such as senescence, genomic instability and drug resistance. These findings revise the current dogma of ubiquitous nucleotide biosynthesis in each proliferating cancer cell in a tumor and suggest that a programmed dTMP distribution maintains collective tumor growth. This mechanism could be exploited in cancer therapy.

cancer biology↗